Aytu Biopharma Inc

Aytu Biopharma Inc has a market price of $2.27, with a market capitalization of $24.36 million, and a price-to-book ratio of 0.79, indicating that the company is trading at a discount to its book value. The company's liquidity position is weak, as evidenced by a current ratio of 0.85, suggesting that it may struggle to meet its short-term obligations with its current assets. The company's free cash flow is negative at -$474,000, and its operating cash flow is also negative at -$600,000, indicating that it is not generating sufficient cash from operations to sustain its activities. The company's profitability is underperforming, with a return on equity of -9.38% and a return on assets of -2.24%, both of which are negative and significantly below the industry median for pharmaceutical companies. The company's operating income is negative at -$1.6 million, and its net income is also negative at -$2.9 million, indicating that it is not currently profitable. The gross profit margin is 74.0%, which is relatively high, but the company's operating and net margins are negative, suggesting that it is not effectively managing its operating expenses. Aytu Biopharma Inc does not disclose segment or geographic revenue data in the provided financial snapshot, so it is not possible to assess the concentration of its revenue across different business lines or regions. However, the company's operations are primarily focused on the United States, as it is a specialty pharmaceutical company that commercializes products in the U.S.. The company's growth trajectory is uncertain, as it is currently reporting negative operating and net income. The provided financial data does not include specific outlook figures for the current or next fiscal year, so it is not possible to quantify the expected growth or decline in revenue. The company's liquidity and profitability challenges suggest that it may face headwinds in achieving sustainable growth in the near term. The risk assessment indicates that Aytu Biopharma Inc has low liquidity and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.54, which is relatively low, but its negative operating cash flow and free cash flow suggest that it may need to rely on external financing to fund its operations. The company's dilution potential is low, and no adjustments have been applied to its valuation metrics. There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The company's financial performance and risk profile suggest that it is in a challenging position, and investors should closely monitor its ability to improve its profitability and liquidity.